ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GALT vs SPRY // RSI-14 & 200D SMA MOMENTUM

Galectin Therapeutics Inc. (NASDAQ) VS. ARS Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: GALT 2 — SPRY 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: GALT
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GALT VS. SPRY) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GALT SPRY SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.71% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -5.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 GALT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 40.7 29.8 +10.88 GALT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $355.8M $364.0M -$8.2M SPRY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GALT REV SPRY REV GALT GROSS % SPRY GROSS % GALT FCF SPRY FCF
FY 2025 $0 $84.3M — — -$23.9M -$171.2M
FY 2024 $0 $89.1M — — -$41.8M $13.0M
FY 2023 $0 $30.0K — — -$33.0M -$59.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GALT // BETA —
SPRY // BETA —